期刊文献+

真武汤对渗透泵恒释ADR肾病综合征大鼠的干预作用 被引量:7

Efficacy of Zhenwu Decoction on Adriamycin-caused Nephritic Syndrome by Osmotic
原文传递
导出
摘要 目的:通过渗透泵恒释技术建立阿霉素肾病综合征(NS)模型,以真武汤干预治疗,评价真武汤对NS大鼠的治疗效果。方法:阿霉素(14.5 mg.kg-1)按渗透泵灌注要求填充,手术植入大鼠腹腔,通过渗透压恒释阿霉素诱发肾病综合征模型,将大鼠随机分为真武汤高、低剂量组(24,12 g.kg-1.d-1),地塞米松组(0.9 mg.kg-1.d-1),给药4周,观察动物一般情况,尿蛋白、血压、血脂、血清蛋白及肾功能指标变化,肾小球IgG表达,评价阿霉素渗透泵肾病综合征模型以及真武汤的干预作用。结果:阿霉素渗透泵NS大鼠成活率显著提高,实验过程中无动物死亡;模型组大鼠第2周出现典型的肾病综合征症状,与空白组比较,24 h尿蛋白、血压、血脂明显升高,血清蛋白及肾功能明显降低(P<0.01);与模型组比较,真武汤高、低剂量组能显著改善NS大鼠精神、活动、摄食量、毛色等状况,明显减轻NS大鼠24 h尿蛋白(109.85±14.65),(49.75±5.14),(51.43±4.46)mg,恢复大鼠血清总蛋白(TP):(57.64±3.64),(61.26±2.21),(60.85±1.91)g.L-1,白蛋白(ALB):(21.70±2.18),(25.93±2.74),(25.00±2.64)g.L-1水平,降低大鼠血清总胆固醇(2.91±0.50),(2.17±0.26),(2.12±0.31)mmol.L-1、甘油三酯(1.05±0.29),(0.49±0.12),(0.61±0.15)mmol.L-1水平,降低大鼠血压、血清尿素氮(BUN)、肌酐(SCr)(P<0.05或P<0.01);减少大鼠肾小球系膜区IgG的沉积。结论:通过渗透泵恒释阿霉素建立肾病综合征模型,可提高造模成功率和模型稳定性,真武汤能减少NS大鼠尿蛋白,提高血浆蛋白水平,减少血液高凝状况,恢复肾功能及肾小球结构,改善NS症状。 Objective: Based on rat adriamycin-caused model of nephritic syndrome (NS) by constant release technology using osmotic pump, to evaluate the efficacy of Zhenwu decoction on NS. Method: Osmotic pump filled with adriamycin (14.5 mg·kg-1) was implanted into rats enterocoelia, then induced the NS on rats by constant release of adriamycin with osmotic pump, and after intervention of Zhenwu decoction, the urine protein, blood pressure, serum lipid parameters, plasmaprotein, renal function indicators, and IgG expression in glomerulus were detected, which was to assess the establishment of model of NS rat and the efficacy of Zhenwu decoction on it. Result: The survival rate of rats with adriamycin-caused NS using osmotic pump was improved significantly, no rats died during experiment.The NS occurred in the rats of model group at second week after giving driamycin, and compared with control group, the urine protein on 24 h and blood pressure were increased significantly after model establishment, and blood lipid, as well as markedly decreased serum protein and renal hypofunction were detected(P〈0.01). Compared with model group, the mental state, activity, food intake and hair colour of rats were observably improved after administrating lower and higher doses of Zhenwu decoction (24, 12 g·kg-1·d-1), and both doses were capable of significantly decreasing urine protein and blood pressure(P〈0.01), recovering rats serum protein level(P〈0.05), improving blood urea nitrogen(BUN) and serum creatinine(Scr) levels, decreasing the content of total cholesterol(TC) and triglycerides(TG) (P〈0.01), and the notably decreased IgG deposition in rats mesangial area. Conclusion: The stable model of rat with NS could be successfully established using constant release function of osmotic pump and after intervention with Zhenwu decoction, it showed the efficacy on improving NS from the aspects of decreasing the urine protein, increasing plasma protein level, relieving hypercoagulable state, the decline in contents of BUN and Scr and restoring glomerular structure.
出处 《中国实验方剂学杂志》 CAS 北大核心 2013年第6期215-219,共5页 Chinese Journal of Experimental Traditional Medical Formulae
基金 广东省自然科学基金委重点项目(S2011020005170) 教育部博士点基金项目(20114425110011)
关键词 肾病综合征 阿霉素 渗透泵 真武汤 nephritic syndrome adriamycin osmotic pump Zhenwu decoction
  • 相关文献

参考文献15

  • 1章友康,刘刚,谌贻璞.肾病综合征的治疗进展和展望[J].临床肾脏病杂志,2008,8(3):137-139. 被引量:14
  • 2侯兆辉,侯志敏.《伤寒论》真武汤方证浅析[J].中国中医急症,2010,19(3):487-487. 被引量:9
  • 3姜岳,邱模炎,孙慧,李葆青.真武汤对慢性肾衰竭大鼠肾功能影响的实验研究[J].中国实验方剂学杂志,2008,14(11):42-44. 被引量:21
  • 4Huang C C, Bazant M Z, Thorsen T. Ultrafast high- pressure AC electro-osmotic pumps for portable biomedical microfluidics [ J ]. Lab Chip, 2010, 10 (1) :80.
  • 5Tuntikulwattana S, Sinchaipanid N, Ketjinda W, et al. Fabrication of chitosan-polyacrylic acid complexes as polymeric osmogents for swellablemicronanoporous osmotic pumps [ J ]. Drug Dev Ind Pharm, 2011, 37(8) :926.
  • 6姚磊,黄栩兵.现代肾病学[M].北京:人民军医出版社,2001:318.
  • 7Guillermo B, Silva Jeffrey L, Garvin. Angiotensin II- dependent hypertension increases Na transport-related oxygen consumption by the thick ascending limb [ J ]. Hypertension, 2008,52 ( 6 ) : 1091.
  • 8Pritam Kanagale, Braj Bhushan Lohray, Ambikanandan Misra, et al. Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin [ J ]. AAPS Pharm Sci Tech,2007,8 ( 3 ) : 53.
  • 9Ebrahimian T, Li M W, Lemarie C A, et al. Mitogen- activated protein kinase-activated protein kinase 2 in angiotensin II-induced inflammation and hypertension: regulation of oxidative stress [ J ]. Hypertension, 2011, 57(2) : 245.
  • 10Ljuca F, G Drevensek, E Zerem. Contribution of Rasfarnesyhransferase, MAP kinase and cytochrome P- 450 metabolites to endothelin-1 induced hypertension [J]. Bosn J Basic Med Sci, 2011,11(2) : 84.

二级参考文献19

共引文献76

同被引文献162

引证文献7

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部